Immune response to racotumomab in a child with relapsed neuroblastoma

Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-gly...

Descripción completa

Detalles Bibliográficos
Autores principales: Sampor, C., Guthmann, M. D., Scursoni, A., Cacciavillano, W., Torbidoni, A., Galluzzo, L., Camarero, S., Lopez, J., de Dávila, M. T. G., Fainboim, L., Chantada, G. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2012
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526767/
https://www.ncbi.nlm.nih.gov/pubmed/23267436
http://dx.doi.org/10.3389/fonc.2012.00195
_version_ 1782253618836013056
author Sampor, C.
Guthmann, M. D.
Scursoni, A.
Cacciavillano, W.
Torbidoni, A.
Galluzzo, L.
Camarero, S.
Lopez, J.
de Dávila, M. T. G.
Fainboim, L.
Chantada, G. L.
author_facet Sampor, C.
Guthmann, M. D.
Scursoni, A.
Cacciavillano, W.
Torbidoni, A.
Galluzzo, L.
Camarero, S.
Lopez, J.
de Dávila, M. T. G.
Fainboim, L.
Chantada, G. L.
author_sort Sampor, C.
collection PubMed
description Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-glycolyl neuraminic acid (NeuGc)- containing gangliosides, eliciting an immune response in a child with relapsed neuroblastoma expressing the NeuGcGM3 ganglioside.
format Online
Article
Text
id pubmed-3526767
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-35267672012-12-24 Immune response to racotumomab in a child with relapsed neuroblastoma Sampor, C. Guthmann, M. D. Scursoni, A. Cacciavillano, W. Torbidoni, A. Galluzzo, L. Camarero, S. Lopez, J. de Dávila, M. T. G. Fainboim, L. Chantada, G. L. Front Oncol Immunology Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-glycolyl neuraminic acid (NeuGc)- containing gangliosides, eliciting an immune response in a child with relapsed neuroblastoma expressing the NeuGcGM3 ganglioside. Frontiers Media S.A. 2012-12-20 /pmc/articles/PMC3526767/ /pubmed/23267436 http://dx.doi.org/10.3389/fonc.2012.00195 Text en Copyright © 2012 Sampor, Guthmann, Scursoni, Cacciavillano, Torbidoni, Galluzzo, Camarero, Lopez, de Dávila, Fainboim and Chantada. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
spellingShingle Immunology
Sampor, C.
Guthmann, M. D.
Scursoni, A.
Cacciavillano, W.
Torbidoni, A.
Galluzzo, L.
Camarero, S.
Lopez, J.
de Dávila, M. T. G.
Fainboim, L.
Chantada, G. L.
Immune response to racotumomab in a child with relapsed neuroblastoma
title Immune response to racotumomab in a child with relapsed neuroblastoma
title_full Immune response to racotumomab in a child with relapsed neuroblastoma
title_fullStr Immune response to racotumomab in a child with relapsed neuroblastoma
title_full_unstemmed Immune response to racotumomab in a child with relapsed neuroblastoma
title_short Immune response to racotumomab in a child with relapsed neuroblastoma
title_sort immune response to racotumomab in a child with relapsed neuroblastoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526767/
https://www.ncbi.nlm.nih.gov/pubmed/23267436
http://dx.doi.org/10.3389/fonc.2012.00195
work_keys_str_mv AT samporc immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma
AT guthmannmd immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma
AT scursonia immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma
AT cacciavillanow immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma
AT torbidonia immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma
AT galluzzol immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma
AT camareros immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma
AT lopezj immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma
AT dedavilamtg immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma
AT fainboiml immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma
AT chantadagl immuneresponsetoracotumomabinachildwithrelapsedneuroblastoma

Ejemplares similares